Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2025-02-04 Report Publication Anno…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Ändrat datum för bokslutskommuniké 2024 för Nanologica AB
Report Publication Announcement Classification · 99% confidence The document is a short announcement in Swedish titled "Ändrat datum för bokslutskommuniké 2024 för Nanologica AB" (Changed date for the 2024 year-end report for Nanologica AB). It explicitly states that the release date for the year-end report (bokslutskommuniké) has been moved to February 14th. Since the document is very short (1633 chars) and its primary function is to announce the publication timing of another report, it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report itself (10-K or IR).
2025-02-04 Swedish
Nanologica Receives Order of NLAB Saga® Worth appx SEK 8.5 Million from Recurring Customer in China
Regulatory Filings Classification · 100% confidence The document is a press release announcing a specific commercial order for the company's product (NLAB Saga) from a customer in China. It is a short, news-style announcement regarding business operations and does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general regulatory announcement regarding company news, it falls under the RNS (Regulatory Filings) category.
2025-01-14 English
Nanologica tar order på NLAB Saga® värd cirka 8,5 MSEK från återkommande kund i Kina
Regulatory Filings Classification · 100% confidence The document is a press release announcing a specific commercial order for the company's product (NLAB Saga) from a customer in China. It provides details on the value of the order and the context of the business relationship. Since it does not fit into specific categories like financial reports, board changes, or dividends, and is a general corporate announcement regarding business operations, it falls under the 'Regulatory Filings' (RNS) category as a standard corporate news release.
2025-01-14 Swedish
Nanologica Receives Order of NLAB Saga® Worth appx SEK 8.5 Million from Recurring Customer in China
Regulatory Filings Classification · 99% confidence The document is a short press release announcing a new sales order (SEK 8.5 Million) from a recurring customer in China for a specific product (NLAB Saga®). It includes commentary from the CEO and standard 'About Us' sections. Crucially, it ends with a statement that the information is made public pursuant to the EU Market Abuse Regulation and lists an attachment link. This structure—a brief announcement of material, non-financial news that is market-sensitive—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general, market-sensitive news releases that are not earnings, dividends, or director dealings.
2025-01-14 English
Nanologica tar order på NLAB Saga® värd cirka 8,5 MSEK från återkommande kund i Kina
Regulatory Filings Classification · 95% confidence The document is a short press release written in Swedish announcing a new order worth approximately 8.5 MSEK from a recurring customer in China for Nanologica's purification media (NLAB Saga®). It includes quotes from the CEO, company background, and contact information. Crucially, the document ends with a statement about being required to disclose information under EU market abuse regulation and lists an attached PDF file. Given its nature as a brief announcement of a specific business event (a new contract/sale) and the presence of an attachment link, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were financial results, but since it's a specific commercial update, RNS is the most appropriate general regulatory announcement category, especially since it's not a formal financial report (10-K, IR, ER). The document length is short (3306 chars), supporting the idea that it is an announcement rather than the full report itself.
2025-01-14 Swedish
Nanologica tar order på NLAB Saga® värd cirka 1,9 MSEK från återkommande kund i Kina
Regulatory Filings Classification · 95% confidence The document is a press release from Nanologica announcing a new commercial order for their product NLAB Saga. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a corporate governance or management change announcement. As it is a general corporate announcement regarding business operations and sales, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous regulatory disclosures.
2024-12-03 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.